YOUR RUNDOWN

Your Restasis rep is getting a new business card.

AbbVie recently finalized its acquisition of Allergan.

A 15-million-dollar mistake.

1-800 Contacts will pay $15.1 million in a price-fixing class action lawsuit after 4 years of litigation. A judge sided with the Federal Trade Commission (FTC) and said that 1-800 Contacts "unlawfully orchestrated a web of anticompetitive agreements," thus restricting price competition.

Wait, what happened exactly?

Here is your 45-second recap.
Search engines such as Google and Bing make money by selling ad space that appears at the top of the results page in response to your search request. Advertisers bid on this top spot via an automated auction and the search engines place the winning bid in this spot. Between 2004 and 2013, 1-800 Contacts sent cease and desist letters to 14 online contact lens vendors to prevent them from bidding on that ad space when the search keywords contained "1-800 Contacts," saying that these vendors were infringing their trademark. Legally, that isn't true, but the other online vendors didn't put up a fight because of the cost of litigation. This meant that even if a user typed "1-800 contacts cheaper competitors" they would only see an ad for 1-800 Contacts, which the FTC considers "restricting price competition." (via)

What does the future of genetic testing in optometry look like?

Read all about it in a new report from CovalentCareers.

Need a second opinion on a case?

There is a new service that can help with that. Telasight is an online platform where you can get a second opinion from some of the best names in optometry. Glance readers get a 10% discount (forever!) on your monthly subscription with the code GLANCE10.


WHAT YOUR PATIENT MIGHT ASK YOU

What is the risk of getting COVID-19 through tears?

Transmission through infected ocular tissue or fluid has been controversial, but according to a new report published in Ophthalmology, the risk is low.

Tell me about the report.

The study included 17 patients who tested positive for COVID-19, all without ocular symptoms on presentation. Tear samples were collected using a Schirmer test strip at 65 varying time points between days 3 and 20 after the initial development of symptoms. Samples were sent to a lab for processing.

What did they find?

Of the 64 samples taken, all tested negative for SARS-CoV-2 on viral isolation and reverse-transcription polymerase chain reaction. All tear samples tested negative even when nasopharyngeal swabs continued to test positive. Most importantly, only one patient developed ocular symptoms during the disease course and no evidence of SARS-CoV-2 could be found in the tear samples. The authors believe this suggests that transmission through tears regardless of the phase of infection is likely to be low.

The take home:

This study found no evidence of SARS-CoV-2 shedding in tears through the course of the disease.


SOCIAL MEDIA ROUNDUP

Have a young patient who is reluctant to wear glasses?

This cat could help.

See you next week!